SCHEMBL4505686

SCHEMBL4505686

Cc1cc(CC(NC(=O)O)c2nc(Br)c[nH]2)cc2cn(COCC[Si](C)(C)C)nc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4500597 0.92 KLKB1 (0.30) —
SCHEMBL4504153 0.91 SSTR3 (0.32) —
SCHEMBL4507863 0.87 CALCRL (0.36) —
SCHEMBL13756227 0.82 SSTR3 (0.32) —
SCHEMBL13756225 0.78 CALCRL (0.34) —
SCHEMBL2973490 0.77 KLKB1 (0.33) —
SCHEMBL2973484 0.77 KLKB1 (0.33) —
SCHEMBL13756203 0.77 AAK1 (0.34) —
SCHEMBL4519405 0.77 CALCRL (0.32) —
SCHEMBL2978647 0.76 PPARG (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569578-B2 Heterocyclic anti-migraine agents BRISTOL-MEYERS SQUIBB COMPANY (US) 2009-08-04 — — US disclosed
EP-1689738-A2 HETEROCYCLIC ANTI-MIGRAINE AGENTS Bristol-Myers Squibb Company (US) 2006-08-16 — — EP disclosed
US-20050153959-A1 3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one; small molecule; non-peptidic; antagonists of calcitonin gene-related peptide receptors (\"CGRP-receptor\"); neurogenic vasodilation and inflammation, cluster headache BRISTOL-MYERS SQUIBB COMPANY 2005-07-14 — — US disclosed
WO-2005056550-A2 HETEROCYCLIC ANTI-MIGRAINE AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-06-23 — — WO disclosed
Send feedback